DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

DISCOVER was the largest PrEP clinical trial, with over 5000 patients1,2

Randomized, active-controlled, double-blind trial1,3

51% were randomized to DESCOVY FOR PrEP™

49% were randomized to continue using TRUVADA

MSM=men who have sex with men; PY=person-years; Q12W=every 12 weeks; TGW=transgender women (who have sex with men).

DISCOVER Trial eligibility required significant risk of acquiring HIV1,4,5